CLOs on the Move


 
Health for health. This describes Zilis. We are building the world`s finest health and wellness brand. Our expert team` headed by Derrick DeSilva` M.D.` brings the latest science to our Ambassadors and customers. We are also founded on the belief that all children deserve adequate nutrition. With every sale` we provide life saving nutrition to children in developing countries.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zilis.com
  • 415 US Highway 377 Street 2020
    Argyle, TX USA 76226
  • Phone: 214.705.3702

Executives

Name Title Contact Details

Similar Companies

Wisteria Cottage

Wisteria Cottage is a Sequim, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stinger Medical

Stinger Medical is a Murfreesboro, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PureLine Genetics

PureLine Genetics is a Preston, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pursuant Health

Empowering the public through free, convenient self-service health care. Formerly SoloHealth.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.